| Row | Study PMID              | Study Name           | Outcome   | Outcome Definition     | Population Type | Population                                      | Subgroup | Cases Total/N Total (Rate %) | Followup | n3 FA       |
|-----|-------------------------|----------------------|-----------|------------------------|-----------------|---|----------|------------------------------|----------|-------------|
| 2   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 3   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 4   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 5   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 6   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 7   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 8   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 9   | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 10  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 11  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 12  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 13  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | EPA+DHA+DPA |
| 14  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 15  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 16  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 17  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 18  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 19  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 20  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 21  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 22  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 23  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 24  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 25  | Dolecek 1992<br>1579579 | MRFIT                | CHD death | Coronary Heart Disease | Healthy         | Men aged 35-57 assigned to the usual care group | Men      | 175/6258 (2.8)               | 10.5 y   | ALA         |
| 26  | Hu 2002<br>11939867     | Nurses' Health Study | CHD death | fatal CHD              | Healthy         | Healthy 34-59 yo female nurses                  | Women    | 484/84688 (0.57)             | 16 y     | EPA+DHA     |

| Row | Study PMID              | n3 measure | Supplement | Adjustments   | Quantile | n3 units |
|-----|-------------------------|------------|------------|---|----------|----------|
| 2   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt1      | g/d      |
| 3   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt2      | g/d      |
| 4   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt3      | g/d      |
| 5   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt4      | g/d      |
| 6   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt5      | g/d      |
| 7   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | All      | g/d      |
| 8   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt1      | % kcal   |
| 9   | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt2      | % kcal   |
| 10  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt3      | % kcal   |
| 11  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt4      | % kcal   |
| 12  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt5      | % kcal   |
| 13  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | All      | % kcal   |
| 14  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt1      | g/d      |
| 15  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt2      | g/d      |
| 16  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt3      | g/d      |
| 17  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt4      | g/d      |
| 18  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt5      | g/d      |
| 19  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | All      | g/d      |
| 20  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt1      | % kcal   |
| 21  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt2      | % kcal   |
| 22  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt3      | % kcal   |
| 23  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt4      | % kcal   |
| 24  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | Qt5      | % kcal   |
| 25  | Dolecek 1992<br>1579579 | Intake     | nd         | age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein  | All      | % kcal   |
| 26  | Hu 2002<br>11939867     | Intake     | no         | age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no) | Qt1      | % kcal   |

| Row | Study PMID              | Quantile low | Quantile median | Quantile high | Metric | n Cases | N quantile | Person Years | Estimate           | CI low | CI high | Comparison | P value |
|-----|-------------------------|--------------|-----------------|---------------|--------|---------|------------|--------------|--------------------|--------|---------|------------|---------|
| 2   | Dolecek 1992<br>1579579 | nd           | 0 (mean)        | nd            | RR     | nd      | 1307       | nd           | Reference<br>group | nd     | nd      |            | <0.05   |
| 3   | Dolecek 1992<br>1579579 | nd           | 0.009 (mean)    | nd            | RR     | nd      | 1197       | nd           | 1.08               | nd     | nd      |            |         |
| 4   | Dolecek 1992<br>1579579 | nd           | 0.046 (mean)    | nd            | RR     | nd      | 1251       | nd           | 0.92               | nd     | nd      |            |         |
| 5   | Dolecek 1992<br>1579579 | nd           | 0.153 (mean)    | nd            | RR     | nd      | 1252       | nd           | 0.89               | nd     | nd      |            |         |
| 6   | Dolecek 1992<br>1579579 | nd           | 0.664 (mean)    | nd            | RR     | nd      | 1251       | nd           | 0.61               | nd     | nd      |            |         |
| 7   | Dolecek 1992<br>1579579 | nd           | nd              | nd            | HR     | 175     | 6258       | nd           | 0.393057251        | nd     | nd      |            | <0.05   |
| 8   | Dolecek 1992<br>1579579 | nd           | 0 (mean)        | nd            | RR     | nd      | 1307       | nd           | Reference<br>group | nd     | nd      |            | <0.05   |
| 9   | Dolecek 1992<br>1579579 | nd           | 0.004 (mean)    | nd            | RR     | nd      | 1196       | nd           | 1.07               | nd     | nd      |            |         |
| 10  | Dolecek 1992<br>1579579 | nd           | 0.019 (mean)    | nd            | RR     | nd      | 1252       | nd           | 0.82               | nd     | nd      |            |         |
| 11  | Dolecek 1992<br>1579579 | nd           | 0.063 (mean)    | nd            | RR     | nd      | 1252       | nd           | 1.12               | nd     | nd      |            |         |
| 12  | Dolecek 1992<br>1579579 | nd           | 0.284 (mean)    | nd            | RR     | nd      | 1251       | nd           | 0.5                | nd     | nd      |            |         |
| 13  | Dolecek 1992<br>1579579 | nd           | nd              | nd            | HR     | 175     | 6258       | nd           | 0.624065468        | nd     | nd      |            | <0.05   |
| 14  | Dolecek 1992<br>1579579 | nd           | 0.873 (mean)    | nd            | RR     | nd      | 1251       | nd           | Reference<br>group | nd     | nd      |            | NS      |
| 15  | Dolecek 1992<br>1579579 | nd           | 1.273 (mean)    | nd            | RR     | nd      | 1253       | nd           | 0.96               | nd     | nd      |            |         |
| 16  | Dolecek 1992<br>1579579 | nd           | 1.577 (mean)    | nd            | RR     | nd      | 1251       | nd           | 0.56               | nd     | nd      |            |         |
| 17  | Dolecek 1992<br>1579579 | nd           | 1.926 (mean)    | nd            | RR     | nd      | 1251       | nd           | 0.96               | nd     | nd      |            |         |
| 18  | Dolecek 1992<br>1579579 | nd           | 2.802 (mean)    | nd            | RR     | nd      | 1252       | nd           | 0.66               | nd     | nd      |            |         |
| 19  | Dolecek 1992<br>1579579 | nd           | nd              | nd            | HR     | 175     | 6258       | nd           | 0.835687951        | nd     | nd      |            | NS      |
| 20  | Dolecek 1992<br>1579579 | nd           | 0.424 (mean)    | nd            | RR     | nd      | 1251       | nd           | Reference<br>group | nd     | nd      |            | <0.05   |
| 21  | Dolecek 1992<br>1579579 | nd           | 0.544 (mean)    | nd            | RR     | nd      | 1252       | nd           | 0.72               | nd     | nd      |            |         |
| 22  | Dolecek 1992<br>1579579 | nd           | 0.63 (mean)     | nd            | RR     | nd      | 1252       | nd           | 0.8                | nd     | nd      |            |         |
| 23  | Dolecek 1992<br>1579579 | nd           | 0.732 (mean)    | nd            | RR     | nd      | 1252       | nd           | 0.61               | nd     | nd      |            |         |
| 24  | Dolecek 1992<br>1579579 | nd           | 0.98 (mean)     | nd            | RR     | nd      | 1251       | nd           | 0.58               | nd     | nd      |            |         |
| 25  | Dolecek 1992<br>1579579 | nd           | nd              | nd            | HR     | 175     | 6258       | nd           | 0.427714227        | nd     | nd      |            | <0.05   |
| 26  | Hu 2002<br>11939867     | nd           | 0.03            | nd            | RR     | 81      | nd         | 255434       | Reference group    | nd     | nd      | P trend    | <0.001  |
| 26  |                         | nd           | 0.03            | nd            | RR     | 81      | nd         | 255434       |                    | nd     | nd      | P trend    | <0.00   |

| Row | Study PMID              | Study Name                       | Outcome   | Outcome Definition    | Population Type | Population                     | Subgroup | Cases Total/N Total (Rate %) | Followup | n3 FA   |
|-----|-------------------------|----------------------------------|-----------|-----------------------|-----------------|--------------------------------|----------|------------------------------|----------|---------|
| 27  | Hu 2002                 | Nurses' Health Study             | CHD death | fatal CHD             | Healthy         | Healthy 34-59 yo female nurses | Women    | 484/84688 (0.57)             | 16 y     | EPA+DHA |
|     | 11939867                |                                  |           |                       |                 |                                |          |                              |          |         |
| 28  | Hu 2002                 | Nurses' Health Study             | CHD death | fatal CHD             | Healthy         | Healthy 34-59 yo female nurses | Women    | 484/84688 (0.57)             | 16 y     | EPA+DHA |
|     | 11939867                |                                  |           |                       |                 |                                |          |                              |          |         |
| 29  | Hu 2002                 | Nurses' Health Study             | CHD death | fatal CHD             | Healthy         | Healthy 34-59 yo female nurses | Women    | 484/84688 (0.57)             | 16 y     | EPA+DHA |
|     | 11939867                |                                  |           |                       |                 |                                |          |                              |          |         |
| 30  | Hu 2002                 | Nurses' Health Study             | CHD death | fatal CHD             | Healthy         | Healthy 34-59 yo female nurses | Women    | 484/84688 (0.57)             | 16 y     | EPA+DHA |
|     | 11939867                |                                  |           |                       |                 |                                |          |                              |          |         |
| 31  | Iso 2006                | Japan Public Health Center-Based | CHD death | Fatal coronary events | Healthy         | Healthy 40-59                  | All      | 62/41578 (0.15)              | 11.5 y   | EPA+DHA |
|     | 16401768                | Study - Cohort I                 |           |                       |                 |                                |          |                              |          |         |
| 32  | Iso 2006                | Japan Public Health Center-Based | CHD death | Fatal coronary events | Healthy         | Healthy 40-59                  | All      | 62/41578 (0.15)              | 11.5 y   | EPA+DHA |
|     | 16401768                | Study - Cohort I                 |           |                       |                 |                                |          |                              |          |         |
| 33  | Iso 2006                | Japan Public Health Center-Based | CHD death | Fatal coronary events | Healthy         | Healthy 40-59                  | All      | 62/41578 (0.15)              | 11.5 y   | EPA+DHA |
|     | 16401768                | Study - Cohort I                 |           |                       |                 |                                |          |                              |          |         |
| 34  | Iso 2006                | Japan Public Health Center-Based | CHD death | Fatal coronary events | Healthy         | Healthy 40-59                  | All      | 62/41578 (0.15)              | 11.5 y   | EPA+DHA |
|     | 16401768                | Study - Cohort I                 |           |                       |                 |                                |          |                              |          |         |
| 35  | Iso 2006                | Japan Public Health Center-Based | CHD death | Fatal coronary events | Healthy         | Healthy 40-59                  | All      | 62/41578 (0.15)              | 11.5 y   | EPA+DHA |
|     | 16401768                | Study - Cohort I                 |           |                       |                 |                                |          |                              |          |         |
| 36  |                         | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 359/3941 (9.11)              | 16y      | EPA     |
|     | 23546563                |                                  |           |                       |                 |                                |          |                              |          |         |
| 37  |                         | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 359/3941 (9.11)              | 16y      | EPA     |
|     | 23546563                |                                  |           |                       |                 |                                |          |                              |          |         |
| 38  |                         | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 359/3941 (9.11)              | 16y      | EPA     |
|     | 23546563                |                                  |           |                       |                 |                                |          |                              |          |         |
| 39  |                         | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 359/3941 (9.11)              | 16y      | EPA     |
|     | 23546563                |                                  |           |                       |                 |                                |          |                              |          |         |
| 40  |                         | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 359/3941 (9.11)              | 16y      | EPA     |
|     | 23546563                |                                  |           |                       |                 |                                |          |                              |          |         |
| 41  | Fretts 2014             | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 280/2583 (10.84)             | 12y      | ALA     |
| 42  | 25159901<br>Fretts 2014 | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 280/2583 (10.84)             | 12y      | ALA     |
|     | 25159901                |                                  |           |                       |                 |                                |          |                              |          |         |
| 43  | Fretts 2014<br>25159901 | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 280/2583 (10.84)             | 12y      | ALA     |
| 44  | Fretts 2014             | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 280/2583 (10.84)             | 12y      | ALA     |
| 45  | 25159901<br>Fretts 2014 | Cardiovascular Health Study      | CHD death | Total CHD mortality   | Healthy         | Healthy age >= 65y             | All      | 280/2583 (10.84)             | 12y      | ALA     |
| -   | 25159901                |                                  |           |                       | ,               | - 7 - 5                        |          |                              | ,        |         |

#### death from coronary heart disease Study PMID Row n3 measure Supplement Adjustments Quantile n3 units 27 Hu 2002 Intake no age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and Ot2 % kcal 11939867 postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no) 28 Hu 2002 Intake age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and Qt3 % kcal no 11939867 postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no) Hu 2002 Intake age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and Qt4 % kcal no 11939867 postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no) 30 Hu 2002 Intake no age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and Qt5 % kcal postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+). 11939867 multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no) 31 age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension Iso 2006 Intake No Qt1 g/d 16401768 and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC. Iso 2006 Intake No age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension Qt2 g/d 16401768 and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC. 33 Iso 2006 Intake No age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension Qt3 g/d 16401768 and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC. Iso 2006 Intake No age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension Qt4 g/d 16401768 and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat. monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC. 35 Iso 2006 Intake No age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension Qt5 g/d 16401768 and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC. Mozaffarian 2013 Plasma % FA no Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch 23546563 (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories). Adjusted for age (years), sex, race (white, nonwhite), education(< high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch Mozaffarian 2013 Plasma % FA no 23546563 (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories). 38 Mozaffarian 2013 Plasma Adjusted for age (years), sex, race (white, nonwhite), education(< high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch Qt3 % FA no 23546563 (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories). 39 Mozaffarian 2013 Plasma Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch % FA no 23546563 (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories). Mozaffarian 2013 Plasma % FA no Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch 23546563 (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories). 41 Fretts 2014 Intake age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension. Qt1 % fat intake no 25159901

age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.

age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.

age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.

age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.

Qt2

Qt3

Qt4

Qt5

% fat intake

% fat intake

% fat intake

% fat intake

42

Fretts 2014

25159901 Fretts 2014

25159901 Fretts 2014

25159901 Fretts 2014

25159901

Intake

Intake

Intake

Intake

no

no

no

no

| Row | Study PMID                   | Quantile low | Quantile median | Quantile high | Metric | n Cases | N quantile | Person Years | Estimate           | CI low | CI high | Comparison | P value |
|-----|------------------------------|--------------|-----------------|---------------|--------|---------|------------|--------------|--------------------|--------|---------|------------|---------|
| 27  | Hu 2002                      | nd           | 0.05            | nd            | RR     | 143     | nd         | 270898       | 0.93               | 0.7    | 1.24    | Companson  | i value |
| _,  | 11939867                     | iid          | 0.00            | nu .          | 141    | 110     | iid        | 210000       | 0.00               | 0.1    | 1.21    |            |         |
| 28  | Hu 2002<br>11939867          | nd           | 0.08            | nd            | RR     | 103     | nd         | 263131       | 0.69               | 0.51   | 0.95    |            |         |
| 29  | Hu 2002<br>11939867          | nd           | 0.14            | nd            | RR     | 73      | nd         | 259454       | 0.54               | 0.39   | 0.76    |            |         |
| 30  | Hu 2002<br>11939867          | nd           | 0.24            | nd            | RR     | 84      | nd         | 258583       | 0.63               | 0.45   | 0.88    |            |         |
| 31  | Iso 2006<br>16401768         | nd           | 0.3 (mean)      | nd            | HR     | 10      | nd         | 102711       | Reference<br>group |        |         | P trend    | 0.1     |
| 32  | Iso 2006<br>16401768         | nd           | 0.6 (mean)      | nd            | HR     | 6       | nd         | 95861        | 0.64               | 0.23   | 1.76    |            |         |
| 33  | Iso 2006<br>16401768         | nd           | 0.9 (mean)      | nd            | HR     | 14      | nd         | 95258        | 1.44               | 0.64   | 3.24    |            |         |
| 34  | Iso 2006<br>16401768         | nd           | 1.3 (mean)      | nd            | HR     | 14      | nd         | 91435        | 1.46               | 0.65   | 3.29    |            |         |
| 35  | Iso 2006<br>16401768         | nd           | 2.1 (mean)      | nd            | HR     | 18      | nd         | 92062        | 1.79               | 0.82   | 3.87    |            |         |
| 36  | Mozaffarian 2013<br>23546563 | nd           | 0.3             | nd            | HR     | nd      | nd         | nd           | Reference<br>group |        |         | P trend    | 0.121   |
| 37  | Mozaffarian 2013<br>23546563 | nd           | 0.41            | nd            | HR     | nd      | nd         | nd           | 0.98               | 0.71   | 1.36    |            |         |
| 38  | Mozaffarian 2013<br>23546563 | nd           | 0.51            | nd            | HR     | nd      | nd         | nd           | 0.94               | 0.68   | 1.31    |            |         |
| 39  | Mozaffarian 2013<br>23546563 | nd           | 0.64            | nd            | HR     | nd      | nd         | nd           | 0.9                | 0.64   | 1.26    |            |         |
| 40  | Mozaffarian 2013<br>23546563 | nd           | 0.92            | nd            | HR     | nd      | nd         | nd           | 0.77               | 0.54   | 1.11    |            |         |
| 41  | Fretts 2014<br>25159901      | 0.39         | 1.33            | 1.45          | HR     | 61      | nd         | 4875         | Reference<br>group |        |         | P trend    | 0.54    |
| 42  | Fretts 2014<br>25159901      | 1.45         | 1.56            | 1.65          | HR     | 55      | nd         | 4987         | 0.89               | 0.62   | 1.29    |            |         |
| 43  | Fretts 2014<br>25159901      | 1.65         | 1.76            | 1.87          | HR     | 50      | nd         | 5096         | 0.83               | 0.57   | 1.21    |            |         |
| 44  | Fretts 2014<br>25159901      | 1.87         | 2               | 2.17          | HR     | 62      | nd         | 5291         | 0.94               | 0.65   | 1.36    |            |         |
| 45  | Fretts 2014<br>25159901      | 2.17         | 2.44            | 4.88          | HR     | 52      | nd         | 5600         | 0.85               | 0.58   | 1.26    |            |         |

| Row | Study PMID                   | Study Name                  | Outcome   | Outcome Definition  | Population Type | Population         | Subgroup | Cases Total/N Total (Rate %) | Followup | n3 FA   |
|-----|------------------------------|-----------------------------|-----------|---------------------|-----------------|--------------------|----------|------------------------------|----------|---------|
| 46  | Fretts 2014<br>25159901      | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 331/2709 (12.22)             | 16y      | ALA     |
| 47  | Fretts 2014<br>25159901      | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 331/2709 (12.22)             | 16y      | ALA     |
| 48  | Fretts 2014<br>25159901      | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 331/2709 (12.22)             | 16y      | ALA     |
| 49  | Fretts 2014<br>25159901      | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 331/2709 (12.22)             | 16y      | ALA     |
| 50  | Fretts 2014<br>25159901      | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 331/2709 (12.22)             | 16y      | ALA     |
| 51  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DPA     |
| 52  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DPA     |
| 53  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DPA     |
| 54  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DPA     |
| 55  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DPA     |
| 56  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | All n-3 |
| 57  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | All n-3 |
| 58  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | All n-3 |
| 59  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | All n-3 |
| 60  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | All n-3 |
| 61  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DHA     |
| 62  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DHA     |
| 63  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DHA     |
| 64  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y | All      | 359/3941 (9.11)              | 16y      | DHA     |
|     |                              |                             |           |                     |                 |                    |          |                              |          |         |

| Row | Study PMID                   | n3 measure | Supplement | Adjustments  | Quantile | n3 units |
|-----|------------------------------|------------|------------|--|----------|----------|
| 46  | Fretts 2014<br>25159901      | Plasma     | no         | age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.  | Qt1      | % FA     |
| 47  | Fretts 2014<br>25159901      | Plasma     | no         | age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.  | Qt2      | % FA     |
| 48  | Fretts 2014<br>25159901      | Plasma     | no         | age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.  | Qt3      | % FA     |
| 49  | Fretts 2014<br>25159901      | Plasma     | no         | age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.  | Qt4      | % FA     |
| 50  | Fretts 2014<br>25159901      | Plasma     | no         | age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.  | Qt5      | % FA     |
| 51  | Mozaffarian 2013<br>23546563 | Plasma     | no         | Adjusted for age (years), sex, race (white, nonwhite), education( <a href="https://righ.com/sin/">https://righ.com/sin/<a href="https://rig&lt;/td&gt;&lt;td&gt;Qt1&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;52&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).&lt;/td&gt;&lt;td&gt;Qt2&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;53&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).&lt;/td&gt;&lt;td&gt;Qt3&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;54&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;a href=" https:="" rightschool.nlm.nlm.nlm.nlm.nlm.nlm.nlm.nlm.nlm.nl<="" td=""><td>Qt4</td><td>% FA</td></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a>   | Qt4      | % FA     |
| 55  | Mozaffarian 2013<br>23546563 | Plasma     | no         | Adjusted for age (years), sex, race (white, nonwhite), education( <a href="https://righ.com/sin/">https://righ.com/sin/<a "="" href="https://rig&lt;/td&gt;&lt;td&gt;Qt5&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;56&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).&lt;/td&gt;&lt;td&gt;Qt1&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;57&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).&lt;/td&gt;&lt;td&gt;Qt2&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;58&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;a href=" https:="" righ.com="" sin="">https://righ.com/sin/<a href="https://righ.com/sin/">https://righ.com/sin/<a "="" href="https://rig&lt;/td&gt;&lt;td&gt;Qt3&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;59&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;a href=" https:="" righ.com="" sin="">https://righ.com/sin/<a href="https://righ.com/sin/">https://righ.com/sin/<a "="" href="https://rig&lt;/td&gt;&lt;td&gt;Qt4&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;60&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).&lt;/td&gt;&lt;td&gt;Qt5&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;61&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;a href=" https:="" righ.com="" sin="">https://righ.com/sin/<a href="https://righ.com/sin/">https://righ.com/sin/<a href="https://rig&lt;/td&gt;&lt;td&gt;Qt1&lt;/td&gt;&lt;td&gt;% FA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;62&lt;/td&gt;&lt;td&gt;Mozaffarian 2013&lt;br&gt;23546563&lt;/td&gt;&lt;td&gt;Plasma&lt;/td&gt;&lt;td&gt;no&lt;/td&gt;&lt;td&gt;Adjusted for age (years), sex, race (white, nonwhite), education(&lt;a href=" https:="" nichols.ncb=""></a>high school"&gt;high school</a>, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).</a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a> | Qt2      | % FA     |
| 63  | Mozaffarian 2013<br>23546563 | Plasma     | no         | Adjusted for age (years), sex, race (white, nonwhite), education( <high (1994–96,="" (4="" (6="" (cm),="" (kg="" (mcal="" (never,="" (yes,="" 2007–10),="" acid="" activity="" alcohol="" and="" atrial="" batch="" body="" categories).<="" circumference="" college="" college,="" current),="" diabetes="" drug-treated="" enrollment="" fatty="" fibrillation="" former,="" graduate),="" high="" hypertension="" index="" leisure-time="" m2),="" mass="" measurement="" no),="" physical="" prevalent="" school,="" site="" sites),="" smoking="" some="" td="" use="" waist="" week),=""><td>Qt3</td><td>% FA</td></high>   | Qt3      | % FA     |
| 64  | Mozaffarian 2013<br>23546563 | Plasma     | no         | Adjusted for age (years), sex, race (white, nonwhite), education( <nigh (1994–96,="" (4="" (6="" (cm),="" (kg="" (mcal="" (never,="" (yes,="" 2007–10),="" acid="" activity="" alcohol="" and="" atrial="" batch="" body="" categories).<="" circumference="" college="" college,="" current),="" diabetes="" drug-treated="" enrollment="" fatty="" fibrillation="" former,="" graduate),="" high="" hypertension="" index="" leisure-time="" m2),="" mass="" measurement="" no),="" physical="" prevalent="" school,="" site="" sites),="" smoking="" some="" td="" use="" waist="" week),=""><td>Qt4</td><td>% FA</td></nigh>   | Qt4      | % FA     |

| Row | Study PMID                   | Quantile low | Quantile median | Quantile high | Metric | n Cases | N quantile | Person Years | Estimate           | CI low | CI high | Comparison | P value |
|-----|------------------------------|--------------|-----------------|---------------|--------|---------|------------|--------------|--------------------|--------|---------|------------|---------|
| 46  | Fretts 2014<br>25159901      | 0.05         | 0.09            | 0.11          | HR     | 101     | nd         | 6483         | Reference<br>group |        |         | P trend    | 0.98    |
| 47  | Fretts 2014<br>25159901      | 0.11         | 0.12            | 0.13          | HR     | 64      | nd         | 6025         | 1.06               | 0.75   | 1.51    |            |         |
| 48  | Fretts 2014<br>25159901      | 0.13         | 0.14            | 0.15          | HR     | 69      | nd         | 6315         | 1.16               | 0.82   | 1.65    |            |         |
| 49  | Fretts 2014<br>25159901      | 0.15         | 0.17            | 0.19          | HR     | 64      | nd         | 6352         | 1.02               | 0.71   | 1.45    |            |         |
| 50  | Fretts 2014<br>25159901      | 0.19         | 0.22            | 0.47          | HR     | 66      | nd         | 6936         | 1.03               | 0.72   | 1.46    |            |         |
| 51  | Mozaffarian 2013<br>23546563 | nd           | 0.63            | nd            | HR     | nd      | nd         | nd           | Reference<br>group |        |         | P trend    | 0.36    |
| 52  | Mozaffarian 2013<br>23546563 | nd           | 0.75            | nd            | HR     | nd      | nd         | nd           | 0.69               | 0.49   | 0.97    |            |         |
| 53  | Mozaffarian 2013<br>23546563 | nd           | 0.82            | nd            | HR     | nd      | nd         | nd           | 0.99               | 0.72   | 1.37    |            |         |
| 54  | Mozaffarian 2013<br>23546563 | nd           | 0.91            | nd            | HR     | nd      | nd         | nd           | 0.82               | 0.59   | 1.15    |            |         |
| 55  | Mozaffarian 2013<br>23546563 | nd           | 1.04            | nd            | HR     | nd      | nd         | nd           | 0.79               | 0.56   | 1.11    |            |         |
| 56  | Mozaffarian 2013<br>23546563 | nd           | 3.17            | nd            | HR     | nd      | nd         | nd           | Reference<br>group |        |         | P trend    | 0.002   |
| 57  | Mozaffarian 2013<br>23546563 | nd           | 3.72            | nd            | HR     | nd      | nd         | nd           | 0.88               | 0.64   | 1.22    |            |         |
| 58  | Mozaffarian 2013<br>23546563 | nd           | 4.21            | nd            | HR     | nd      | nd         | nd           | 1.03               | 0.75   | 1.41    |            |         |
| 59  | Mozaffarian 2013<br>23546563 | nd           | 4.8             | nd            | HR     | nd      | nd         | nd           | 0.62               | 0.43   | 0.89    |            |         |
| 60  | Mozaffarian 2013<br>23546563 | nd           | 6.04            | nd            | HR     | nd      | nd         | nd           | 0.6                | 0.42   | 0.87    |            |         |
| 61  | Mozaffarian 2013<br>23546563 | nd           | 1.95            | nd            | HR     | nd      | nd         | nd           | Reference<br>group |        |         | P trend    | 0.003   |
| 62  | Mozaffarian 2013<br>23546563 | nd           | 2.44            | nd            | HR     | nd      | nd         | nd           | 0.98               | 0.71   | 1.36    |            |         |
| 63  | Mozaffarian 2013<br>23546563 | nd           | 2.87            | nd            | HR     | nd      | nd         | nd           | 0.96               | 0.69   | 1.32    |            |         |
| 64  | Mozaffarian 2013<br>23546563 | nd           | 3.36            | nd            | HR     | nd      | nd         | nd           | 0.77               | 0.55   | 1.08    |            |         |
|     |                              |              |                 |               |        |         |            |              |                    |        |         |            |         |

| Row | Study PMID                   | Study Name   | Outcome   | Outcome Definition  | Population Type | Population                             | Subgroup | Cases Total/N Total (Rate %) | Followup | n3 FA   |
|-----|------------------------------|--|-----------|---------------------|-----------------|--|----------|------------------------------|----------|---------|
| 65  | Mozaffarian 2013<br>23546563 | Cardiovascular Health Study                            | CHD death | Total CHD mortality | Healthy         | Healthy age >= 65y                     | All      | 359/3941 (9.11)              | 16y      | DHA     |
| 66  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA+DHA |
| 67  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA+DHA |
| 68  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA+DHA |
| 69  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA+DHA |
| 70  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | All n-3 |
| 71  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | All n-3 |
| 72  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | All n-3 |
| 73  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | All n-3 |
| 74  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA     |
| 75  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA     |
| 76  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA     |
| 77  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | EPA     |
| 78  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | DHA     |
| 79  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | DHA     |
| 80  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | DHA     |
| 81  | Miyagawa 2014<br>24468152    | NIPPON DATA80  | CHD death | CHD                 | Healthy         | healthy individual with mean age of 50 | All      | 171/9190 (1.86)              | 24 y     | DHA     |
| 82  | Pietinen 1997<br>9149659     | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention | CHD death | coronary death      | Healthy         | health smoking men aged 50-69 years    | Men      | 581/21930 (2.65)             | 6 y      | ALA     |
| 83  | Pietinen 1997<br>9149659     | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention | CHD death | coronary death      | Healthy         | health smoking men aged 50-69 years    | Men      | 581/21930 (2.65)             | 6 y      | ALA     |
| 84  | Pietinen 1997<br>9149659     | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention | CHD death | coronary death      | Healthy         | health smoking men aged 50-69 years    | Men      | 581/21930 (2.65)             | 6 y      | ALA     |
| 85  | Pietinen 1997<br>9149659     | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention | CHD death | coronary death      | Healthy         | health smoking men aged 50-69 years    | Men      | 581/21930 (2.65)             | 6 y      | ALA     |
| 86  | Pietinen 1997<br>9149659     | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention | CHD death | coronary death      | Healthy         | health smoking men aged 50-69 years    | Men      | 581/21930 (2.65)             | 6 y      | ALA     |
|     |                              |  |           |                     |                 |  |          |                              |          |         |

death from coronary heart disease

#### Study PMID Row n3 measure Supplement Adjustments Quantile n3 units 65 Mozaffarian 2013 Plasma no Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch % FA 23546563 (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories). 66 Miyagawa 2014 Intake age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr1 % kcal nο 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 67 Miyagawa 2014 Intake age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr2 % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Miyagawa 2014 Qr3 Intake no age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 69 Miyagawa 2014 Intake age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr4 % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Miyaqawa 2014 age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Intake Qr1 % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Qr2 71 Miyagawa 2014 Intake no age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Miyagawa 2014 Intake no age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr3 % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Miyagawa 2014 age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total 73 Intake Qr4 no % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 74 Qr1 Miyagawa 2014 Intake age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Miyagawa 2014 age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr2 75 Intake % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Or3 76 Miyagawa 2014 Intake nο age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 77 Miyagawa 2014 Intake age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr4 % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 78 Miyagawa 2014 Intake Qr1 age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 79 Miyagawa 2014 age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr2 % kcal no cholesterol, body mass index, antihypertensive medication status and residential area 24468152 age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Miyagawa 2014 Intake no Qr3 % kcal 24468152 cholesterol, body mass index, antihypertensive medication status and residential area 81 Miyagawa 2014 Intake age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total Qr4 % kcal no 24468152 cholesterol, body mass index, antihypertensive medication status and residential area Pietinen 1997 age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 Qt1 Intake q/d no 9149659 times per week). 83 Pietinen 1997 Intake age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 Qt2 q/d no 9149659 Pietinen 1997 Intake no age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 Qt3 g/d 9149659 Pietinen 1997 age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 Qt4 Intake nο g/d 9149659 times per week). Intake age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 Qt5 Pietinen 1997 g/d no 9149659 times per week).

| Row        | Study PMID                   | Quantile low            | Quantile median      | Quantile high           | Metric | n Cases | N quantile | Person Years | Estimate | CI low | CI high | Comparison              | P value |
|------------|------------------------------|-------------------------|----------------------|-------------------------|--------|---------|------------|--------------|----------|--------|---------|-------------------------|---------|
| 65         | Mozaffarian 2013<br>23546563 | nd                      | 4.34                 | nd                      | HR     | nd      | nd         | nd           | 0.6      | 0.41   | 0.87    |                         |         |
| 66         | Miyagawa 2014<br>24468152    | men 0.00,<br>women 0.02 | men 0.18, women 0.19 | men 0.23, women 0.25    | HR     | 39      | nd         | 47402        | 1        | nd     | nd      | overal effect for trend | 0.713   |
| 67         | Miyagawa 2014<br>24468152    | men 0.24,<br>women 0.26 | men 0.29, women 0.32 | men 0.35, women 0.38    | HR     | 43      | nd         | 50196        | 1.01     | 0.66   | 1.57    |                         |         |
| 88         | Miyagawa 2014<br>24468152    | men 0.36,<br>women 0.39 | men 0.43, women 0.46 | men 0.51, women 0.55    | HR     | 43      | nd         | 47359        | 0.95     | 0.61   | 1.46    |                         |         |
| 69         | Miyagawa 2014<br>24468152    | men 0.52,<br>women 0.56 | men 0.65, women 0.70 | men 2.34 women 2.43     | HR     | 46      | nd         | 47940        | 0.94     | 0.61   | 1.45    |                         |         |
| 70         | Miyagawa 2014<br>24468152    | men 0.20,<br>women 0.21 | nd                   | men 0.85, women 0.93    | HR     | 52      | nd         | 45771        | 1        | nd     | nd      | overal effect for trend | 0.395   |
| 71         | Miyagawa 2014<br>24468152    | men 0.86,<br>women 0.94 | nd                   | men 1.05, women<br>1.15 | HR     | 47      | nd         | 49814        | 1.06     | 0.71   | 1.57    |                         |         |
| 72         | Miyagawa 2014<br>24468152    | men 1.06,<br>women 1.16 | nd                   | men 1.28, women<br>1.39 | HR     | 34      | nd         | 48876        | 0.81     | 0.52   | 1.25    |                         |         |
| 73         | Miyagawa 2014<br>24468152    | men 1.29,<br>women 1.40 | nd                   | men 3.92 women<br>3.66  | HR     | 38      | nd         | 48438        | 0.89     | 0.58   | 1.36    |                         |         |
| 74         | Miyagawa 2014<br>24468152    | men 0.00,<br>women 0.00 | nd                   | men 0.08, women 0.09    | HR     | 41      | nd         | 49312        | 1        | nd     | nd      | overal effect for trend | 0.518   |
| <b>'</b> 5 | Miyagawa 2014<br>24468152    | men 0.09,<br>women 0.10 | nd                   | men 0.13, women 0.14    | HR     | 44      | nd         | 49840        | 1.01     | 0.66   | 1.54    |                         |         |
| <b>'</b> 6 | Miyagawa 2014<br>24468152    | men 0.14,<br>women 0.15 | nd                   | men 0.19, women<br>0.21 | HR     | 41      | nd         | 45546        | 0.92     | 0.59   | 1.42    |                         |         |
| 77         | Miyagawa 2014<br>24468152    | men 0.20,<br>women 0.22 | nd                   | men 0.95, women<br>0.98 | HR     | 45      | nd         | 48200        | 0.89     | 0.58   | 1.36    |                         |         |
| 78         | Miyagawa 2014<br>24468152    | men 0.00,<br>women 0.10 | nd                   | men 0.15, women 0.16    | HR     | 40      | nd         | 49413        | 1        | nd     | nd      | overal effect for trend | 0.565   |
| 79         | Miyagawa 2014<br>24468152    | men 0.16,<br>women 0.17 | nd                   | men 0.22, women 0.23    | HR     | 43      | nd         | 46366        | 1.11     | 0.72   | 1.71    |                         |         |
| 80         | Miyagawa 2014<br>24468152    | men 0.23,<br>women 0.24 | nd                   | men 0.31, women 0.34    | HR     | 44      | nd         | 50022        | 0.96     | 0.63   | 1.48    |                         |         |
| 31         | Miyagawa 2014<br>24468152    | men 0.32,<br>women 0.35 | nd                   | men 1.39, women<br>1.45 | HR     | 44      | nd         | 47097        | 0.94     | 0.61   | 1.44    |                         |         |
| 82         | Pietinen 1997<br>9149659     | nd                      | 0.9                  | nd                      | RR     | 149     | nd         | 25277        | 1        | nd     | nd      | Overall Test for trend  | 0.77    |
| 83         | Pietinen 1997<br>9149659     | nd                      | 1.2                  | nd                      | RR     | 127     | nd         | 25821        | 0.8      | 0.94   | 1.11    |                         |         |
| 34         | Pietinen 1997<br>9149659     | nd                      | 1.5                  | nd                      | RR     | 124     | nd         | 26226        | 0.84     | 0.99   | 1.17    |                         |         |
| 35         | Pietinen 1997<br>9149659     | nd                      | 1.9                  | nd                      | RR     | 122     | nd         | 25961        | 0.86     | 1.01   | 1.2     |                         |         |
| 36         | Pietinen 1997<br>9149659     | nd                      | 2.5                  | nd                      | RR     | 113     | nd         | 26103        | 0.8      | 0.96   | 1.14    |                         |         |
|            |                              |                         |                      |                         |        |         |            |              |          |        |         |                         |         |

| Row | Study PMID                 | Study Name  | Outcome   | Outcome Definition           | Population Type | Population                          | Subgroup | Cases Total/N Total (Rate %) | Followup                   | n3 FA       |
|-----|----------------------------|---|-----------|------------------------------|-----------------|-------------------------------------|----------|------------------------------|----------------------------|-------------|
| 87  | Pietinen 1997<br>9149659   | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention            | CHD death | coronary death               | Healthy         | health smoking men aged 50-69 years | Men      | 581/21930 (2.65)             | 6 y                        | EPA+DHA+DPA |
| 88  | Pietinen 1997<br>9149659   | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention            | CHD death | coronary death               | Healthy         | health smoking men aged 50-69 years | Men      | 581/21930 (2.65)             | 6 y                        | EPA+DHA+DPA |
| 89  | Pietinen 1997<br>9149659   | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention            | CHD death | coronary death               | Healthy         | health smoking men aged 50-69 years | Men      | 581/21930 (2.65)             | 6 y                        | EPA+DHA+DPA |
| 90  | Pietinen 1997<br>9149659   | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention            | CHD death | coronary death               | Healthy         | health smoking men aged 50-69 years | Men      | 581/21930 (2.65)             | 6 y                        | EPA+DHA+DPA |
| 91  | Pietinen 1997<br>9149659   | Alpha-Tocopherol Beta-Carotene<br>Cancer<br>Prevention            | CHD death | coronary death               | Healthy         | health smoking men aged 50-69 years | Men      | 581/21930 (2.65)             | 6 y                        | EPA+DHA+DPA |
| 92  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA         |
| 93  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA         |
| 94  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA         |
| 95  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA         |
| 96  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA         |
| 97  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | DHA         |
| 98  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | DHA         |
| 99  | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | DHA         |
| 100 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | DHA         |
| 101 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | DHA         |
| 102 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA+DHA     |
| 103 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA+DHA     |
| 104 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA+DHA     |
| 105 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA+DHA     |
| 106 | Takata 2013<br>23788668    | Shanghai Women's and Men's Health Studies                         | CHD death | ischemic heart disease death | Healthy         | Healthy 40-74                       | All      | 5836/134296 (4.35)           | 11.2 y women; 5.6<br>y men | EPA+DHA     |
| 107 | Vedtofte 2014<br>24964401  | Pooling Project of Cohort Studies on<br>Diet and Coronary Disease | CHD death | fatal CHD                    | Healthy         | healthy 49 to 61 y                  | All      | 1751/229043 (0.76)           | 4-10 y                     | ALA         |
| 108 | Yamagishi 2008<br>18786479 | JACC  | CHD death | ischemic heart disease death | Healthy         | Healthy 40-79 yo                    | All      | 419/57972 (0.72)             | 12.7 y                     | All n-3     |
| 109 | Yamagishi 2008<br>18786479 | JACC  | CHD death | ischemic heart disease death | Healthy         | Healthy 40-79 yo                    | All      | 419/57972 (0.72)             | 12.7 y                     | All n-3     |

| Row | Study PMID                 | n3 measure | Supplement             | Adjustments  | Quantile | n3 units |
|-----|----------------------------|------------|------------------------|--|----------|----------|
| 87  | Pietinen 1997<br>9149659   | Intake     | no                     | age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 times per week).  | Qt1      | g/d      |
| 88  | Pietinen 1997<br>9149659   | Intake     | no                     | age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 times per week).  | Qt2      | g/d      |
| 89  | Pietinen 1997<br>9149659   | Intake     | no                     | age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 times per week).  | Qt3      | g/d      |
| 90  | Pietinen 1997<br>9149659   | Intake     | no                     | age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 times per week).  | Qt4      | g/d      |
| 91  | Pietinen 1997<br>9149659   | Intake     | no                     | age, treatment group, smoking, body mass index, blood pressure, intakes of energy, alcohol, and fiber (quintiles), education (<7, 7-11, >11 years), and physical activity (<1, 1-2, >2 times per week).  | Qt5      | g/d      |
| 92  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt1      | g/d      |
| 93  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt2      | g/d      |
| 94  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt3      | g/d      |
| 95  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt4      | g/d      |
| 96  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt5      | g/d      |
| 97  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt1      | g/d      |
| 98  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt2      | g/d      |
| 99  | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt3      | g/d      |
| 100 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt4      | g/d      |
| 101 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt5      | g/d      |
| 102 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt1      | g/d      |
| 103 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt2      | g/d      |
| 104 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt3      | g/d      |
| 105 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt4      | g/d      |
| 106 | Takata 2013<br>23788668    | Intake     | No                     | age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only). | Qt5      | g/d      |
| 107 | Vedtofte 2014<br>24964401  | Intake     | NA (no ALA supplement) | age at baseline, calendar year, smoking habits, BMI, physical activity, educational level, history of hypertension, alcohol intake, total energy intake (where alcohol is excluded), fiber intake, MUFA, SFA, trans-fatty acid, long-chain n-3 FA, and linoleic acid intake  | All      | g/d      |
| 108 | Yamagishi 2008<br>18786479 | Intake     | No                     | age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit  | Qt1      | g/d      |
| 109 | Yamagishi 2008<br>18786479 | Intake     | No                     | age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit  | Qt2      | g/d      |

| Row | Study PMID                 | Quantile low | Quantile median               | Quantile high | Metric | n Cases | N quantile | Person Years | Estimate           | CI low | CI high | Comparison             | P value |
|-----|----------------------------|--------------|-------------------------------|---------------|--------|---------|------------|--------------|--------------------|--------|---------|------------------------|---------|
| 87  | Pietinen 1997<br>9149659   | nd           | 0.2                           | nd            | RR     | 126     | nd         | 26032        | 1                  | nd     | nd      | Overall Test for trend | 0.118   |
| 88  | Pietinen 1997<br>9149659   | nd           | 0.3                           | nd            | RR     | 114     | nd         | 26081        | 0.8                | 0.94   | 1.12    |                        |         |
| 89  | Pietinen 1997<br>9149659   | nd           | 0.4                           | nd            | RR     | 120     | nd         | 29590        | 0.87               | 1.03   | 1.21    |                        |         |
| 90  | Pietinen 1997<br>9149659   | nd           | 0.5                           | nd            | RR     | 130     | nd         | 25855        | 0.86               | 1.02   | 1.2     |                        |         |
| 91  | Pietinen 1997<br>9149659   | nd           | 0.8                           | nd            | RR     | 145     | nd         | 25470        | 0.97               | 1.15   | 1.35    |                        |         |
| 92  | Takata 2013<br>23788668    | nd           | 0.006 (men), 0.005<br>(women) | nd            | HR     | 187     | 26860      | nd           | Reference group    |        |         | P trend                | 0.25    |
| 93  | Takata 2013<br>23788668    | nd           | 0.01 (men), 0.01<br>(women)   | nd            | HR     | 102     | nd         | nd           | 0.83               | 0.64   | 1.06    |                        |         |
| 94  | Takata 2013<br>23788668    | nd           | 0.02 (men), 0.02<br>(women)   | nd            | HR     | 70      | 26860      | nd           | 0.71               | 0.53   | 0.95    |                        |         |
| 95  | Takata 2013<br>23788668    | nd           | 0.03 (men), 0.03<br>(women)   | nd            | HR     | 57      | nd         | nd           | 0.71               | 0.52   | 0.98    |                        |         |
| 96  | Takata 2013<br>23788668    | nd           | 0.07 (men), 0.06<br>(women)   | nd            | HR     | 60      | 26858      | nd           | 0.84               | 0.6    | 1.16    |                        |         |
| 97  | Takata 2013<br>23788668    | nd           | 0.009 (men), 0.008<br>(women) | nd            | HR     | 194     | 26860      | nd           | Reference<br>group |        |         | P trend                | 0.31    |
| 98  | Takata 2013<br>23788668    | nd           | 0.02 (men), 0.02<br>(women)   | nd            | HR     | 91      | nd         | nd           | 0.72               | 0.51   | 1       |                        |         |
| 99  | Takata 2013<br>23788668    | nd           | 0.05 (men), 0.04<br>(women)   | nd            | HR     | 67      | 26860      | nd           | 0.65               | 0.47   | 0.9     |                        |         |
| 100 | Takata 2013<br>23788668    | nd           | 0.08 (men), 0.08<br>(women)   | nd            | HR     | 65      | nd         | nd           | 0.76               | 0.56   | 1.02    |                        |         |
| 101 | Takata 2013<br>23788668    | nd           | 0.15 (men), 0.15<br>(women)   | nd            | HR     | 59      | 26858      | nd           | 0.79               | 0.57   | 1.09    |                        |         |
| 102 | Takata 2013<br>23788668    | nd           | nd                            | nd            | HR     | 195     | 26860      | nd           | Reference group    |        |         | P trend                | 0.31    |
| 103 | Takata 2013<br>23788668    | nd           | nd                            | nd            | HR     | 91      | nd         | nd           | 0.72               | 0.55   | 0.93    |                        |         |
| 104 | Takata 2013<br>23788668    | nd           | nd                            | nd            | HR     | 66      | 26860      | nd           | 0.64               | 0.48   | 0.86    |                        |         |
| 105 | Takata 2013<br>23788668    | nd           | nd                            | nd            | HR     | 65      | nd         | nd           | 0.76               | 0.57   | 1.03    |                        |         |
| 106 | Takata 2013<br>23788668    | nd           | nd                            | nd            | HR     | 59      | 26858      | nd           | 0.79               | 0.57   | 1.09    |                        |         |
| 107 | Vedtofte 2014<br>24964401  | nd           | nd                            | nd            | HR     | nd      | nd         | nd           | 0.88               | 0.68   | 1.14    | per g/d increase       |         |
| 108 | Yamagishi 2008<br>18786479 | 0.05         | nd                            | 1.18          | HR     | 75      | 11594      | 735904       | Reference<br>group |        |         |                        | 0.58    |
| 109 | Yamagishi 2008<br>18786479 | 1.18         | nd                            | 1.47          | HR     | 86      | 11595      | 735904       | 1.17               | 0.84   | 1.62    |                        |         |

| Row | Study PMID                 | Study Name                         | Outcome   | Outcome Definition           | Population Type | Population       | Subgroup | Cases Total/N Total (Rate %) | Followup | n3 FA   |
|-----|----------------------------|------------------------------------|-----------|------------------------------|-----------------|------------------|----------|------------------------------|----------|---------|
| 110 | Yamagishi 2008<br>18786479 | JACC                               | CHD death | ischemic heart disease death | Healthy         | Healthy 40-79 yo | All      | 419/57972 (0.72)             | 12.7 y   | All n-3 |
| 111 | Yamagishi 2008<br>18786479 | JACC                               | CHD death | ischemic heart disease death | Healthy         | Healthy 40-79 yo | All      | 419/57972 (0.72)             | 12.7 y   | All n-3 |
| 112 | Yamagishi 2008<br>18786479 | JACC                               | CHD death | ischemic heart disease death | Healthy         | Healthy 40-79 yo | All      | 419/57972 (0.72)             | 12.7 y   | All n-3 |
| 113 | de Goede 2010<br>20335635  | MORGEN                             | CHD death | fatal CHD                    | Healthy         | Healthy 20-65 yo | All      | 82/21055 (0.39)              | 11.3 y   | EPA+DHA |
| 114 | de Goede 2010<br>20335635  | MORGEN                             | CHD death | fatal CHD                    | Healthy         | Healthy 20-65 yo | All      | 82/21055 (0.39)              | 11.3 y   | EPA+DHA |
| 115 | de Goede 2010<br>20335635  | MORGEN                             | CHD death | fatal CHD                    | Healthy         | Healthy 20-65 yo | All      | 82/21055 (0.39)              | 11.3 y   | EPA+DHA |
| 116 | de Goede 2010<br>20335635  | MORGEN                             | CHD death | fatal CHD                    | Healthy         | Healthy 20-65 yo | All      | 82/21055 (0.39)              | 11.3 y   | EPA+DHA |
| 117 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 118 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 119 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5y       | All n-3 |
| 120 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5y       | All n-3 |
| 121 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 122 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 123 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 124 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 125 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 126 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 126 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
| 126 | Koh_2013_243438<br>44      | The Singapore Chinese Health Study | CHD death |                              | Healthy         |                  | All      | 2697/60298 (0.05)            | 5у       | All n-3 |
|     |                            |                                    |           |                              |                 |                  |          |                              |          |         |

#### death from coronary heart disease

| Row | Study PMID                 | n3 measure | Supplement | Adjustments   | Quantile | n3 units |
|-----|----------------------------|------------|------------|---|----------|----------|
| 110 | Yamagishi 2008<br>18786479 | Intake     | No         | age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit   | Qt3      | g/d      |
| 111 | Yamagishi 2008<br>18786479 | Intake     | No         | age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit   | Qt4      | g/d      |
| 112 | Yamagishi 2008<br>18786479 | Intake     | No         | age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit   | Qt5      | g/d      |
| 113 | de Goede 2010<br>20335635  | Intake     | No         | age, gender, BMI, total energy intake, ethanol intake, cigarette smoking, social economic status, vitamin/mineral supplement use, use of drugs for hypertension/hypercholesterolemia, family history of CVD, SFA, fruit, and vegetables   | Qt1      | g/d      |
| 114 | de Goede 2010<br>20335635  | Intake     | No         | age, gender, BMI, total energy intake, ethanol intake, cigarette smoking, social economic status, vitamin/mineral supplement use, use of drugs for hypertension/hypercholesterolemia, family history of CVD, SFA, fruit, and vegetables   | Qt2      | g/d      |
| 115 | de Goede 2010<br>20335635  | Intake     | No         | age, gender, BMI, total energy intake, ethanol intake, cigarette smoking, social economic status, vitamin/mineral supplement use, use of drugs for hypertension/hypercholesterolemia, family history of CVD, SFA, fruit, and vegetables   | Qt3      | g/d      |
| 116 | de Goede 2010<br>20335635  | Intake     | No         | age, gender, BMI, total energy intake, ethanol intake, cigarette smoking, social economic status, vitamin/mineral supplement use, use of drugs for hypertension/hypercholesterolemia, family history of CVD, SFA, fruit, and vegetables   | Qt4      | g/d      |
| 117 | Koh_2013_243438<br>44      | B Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr1      | nd       |
| 118 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr2      | nd       |
| 119 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr3      | nd       |
| 120 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr4      | nd       |
| 121 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr1      | nd       |
| 122 | Koh_2013_243438<br>44      | B Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr2      | nd       |
| 123 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr3      | nd       |
| 124 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr4      | nd       |
| 125 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr1      | nd       |
| 126 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr2      | nd       |
| 126 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr3      | nd       |
| 126 | Koh_2013_243438<br>44      | 8 Intake   | No         | age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA) | Qr4      | nd       |
|     |                            |            |            |   |          |          |

| Row | Study PMID                 | Quantile low | Quantile median | Quantile high | Metric | n Cases | N quantile | Person Years | Estimate           | CI low | CI high | Comparison   | P value |
|-----|----------------------------|--------------|-----------------|---------------|--------|---------|------------|--------------|--------------------|--------|---------|--------------|---------|
| 110 | Yamagishi 2008             | 1.47         | nd              | 1.75          | HR     | 78      | 11594      | 735904       | 0.98               | 0.69   | 1.4     | - Companison |         |
|     | 18786479                   |              |                 |               |        |         |            |              |                    |        |         |              |         |
| 111 | Yamagishi 2008<br>18786479 | 1.75         | nd              | 2.11          | HR     | 81      | 11595      | 735904       | 1                  | 0.68   | 1.45    |              |         |
| 112 | Yamagishi 2008<br>18786479 | 2.11         | nd              | 5.06          | HR     | 99      | 11594      | 735904       | 0.95               | 0.62   | 1.43    |              |         |
| 113 | de Goede 2010<br>20335635  | nd           | 40              | <62           | HR     | 24      | 5336       | nd           | Reference<br>group |        |         | P trend      | 0.05    |
| 114 | de Goede 2010<br>20335635  | 62           | 84              | 113           | HR     | 18      | 5335       | nd           | 0.68               | 0.36   | 1.25    |              |         |
| 115 | de Goede 2010<br>20335635  | 114          | 151             | 194           | HR     | 20      | 5335       | nd           | 0.65               | 0.36   | 1.19    |              |         |
| 116 | de Goede 2010<br>20335635  | >194         | 234             | nd            | HR     | 20      | 5336       | nd           | 0.51               | 0.27   | 0.94    |              |         |
| 117 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 726     | 15181      |              | Ref                |        |         | P trend      | 0.04    |
| 118 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 678     | 15022      |              | 0.92               | 0.81   | 1.03    |              |         |
| 119 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 675     | 15023      |              | 0.92               | 0.8    | 1.03    |              |         |
| 120 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 618     | 15072      |              | 0.85               | 0.73   | 0.98    |              |         |
| 121 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 680     | 15181      |              | Ref                |        |         | P trend      | 0.02    |
| 122 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 689     | 15022      |              | 0.99               | 0.88   | 1.1     |              |         |
| 123 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 700     | 15023      |              | 0.97               | 0.85   | 1.09    |              |         |
| 124 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 628     | 15072      |              | 0.86               | 0.74   | 0.99    |              |         |
| 125 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 730     | 15181      |              | Ref                |        |         | P trend      | 0.001   |
| 126 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 733     | 15022      |              | 1.01               | 0.9    | 1.13    |              |         |
| 126 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 651     | 15023      |              | 0.9                | 0.79   | 1.01    |              |         |
| 126 | Koh_2013_243438<br>44      | nd           | nd              | nd            | HR     | 583     | 15072      |              | 0.82               | 0.71   | 0.93    |              |         |
|     |                            |              |                 |               |        |         |            |              |                    |        |         |              |         |

| Row | Study PMID                | Study Name  | Outcome   | Outcome Definition | Population Type | ulation Type Population |       | Cases Total/N Total (Rate %) | Followup | n3 FA |
|-----|---------------------------|---|-----------|--------------------|-----------------|-------------------------|-------|------------------------------|----------|-------|
|     |                           |   |           |                    |                 |                         |       |                              |          |       |
| 128 | Subgroup                  |   |           |                    |                 |                         |       |                              |          |       |
|     | analyses                  |   |           |                    |                 |                         |       |                              |          |       |
| 129 | Vedtofte 2014             | Pooling Project of Cohort Studies on                              | CHD death | fatal CHD          | Healthy         | healthy 49 to 61 y      | Women | 560/148675 (0.38)            | 4-10 y   | ALA   |
|     | 24964401                  | Diet and Coronary Disease   |           |                    |                 |                         |       |                              |          |       |
| 130 | Vedtofte 2014<br>24964401 | Pooling Project of Cohort Studies on<br>Diet and Coronary Disease | CHD death | fatal CHD          | Healthy         | healthy 49 to 61 y      | Men   | 1191/80368 (1.48)            | 4-10 y   | ALA   |

| Row | Study PMID                | n3 measure | Supplement             | Adjustments   | Quantile | n3 units |
|-----|---------------------------|------------|------------------------|---|----------|----------|
|     |                           |            |                        |   |          |          |
| 128 | Subgroup                  |            |                        |   |          |          |
|     | analyses                  |            |                        |   |          |          |
| 129 | Vedtofte 2014             | Intake     | NA (no ALA             | age at baseline, calendar year, smoking habits, BMI, physical activity, educational level, history of hypertension, alcohol intake, total energy intake (where alcohol is excluded), fiber  | All      | g/d      |
|     | 24964401                  |            | supplement)            | intake, MUFA, SFA, trans-fatty acid, long-chain n-3 FA, and linoleic acid intake  |          |          |
| 130 | Vedtofte 2014<br>24964401 | Intake     | NA (no ALA supplement) | age at baseline, calendar year, smoking habits, BMI, physical activity, educational level, history of hypertension, alcohol intake, total energy intake (where alcohol is excluded), fiber intake, MUFA, SFA, trans-fatty acid, long-chain n-3 FA, and linoleic acid intake | All      | g/d      |

| Row | Study PMID                | Quantile low | Quantile median | Quantile high | Metric | n Cases | N quantile | Person Years | Estimate | CI low | CI high | Comparison       | P value |
|-----|---------------------------|--------------|-----------------|---------------|--------|---------|------------|--------------|----------|--------|---------|------------------|---------|
|     |                           | ·            |                 |               |        |         |            |              |          |        |         |                  |         |
| 128 | Subgroup analyses         |              |                 |               |        |         |            |              |          |        |         |                  |         |
| 129 | Vedtofte 2014<br>24964401 | nd           | nd              | nd            | HR     | nd      | nd         | nd           | 1.23     | 0.8    | 1.89    | per g/d increase |         |
| 130 | Vedtofte 2014<br>24964401 | nd           | nd              | nd            | HR     | nd      | nd         | nd           | 0.77     | 0.58   | 1.01    | per g/d increase |         |